Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1.

Hamuro L, Tirucherai GS, Crawford SM, Nayeem A, Pillutla RC, DeSilva BS, Leil TA, Thalhauser CJ.

AAPS J. 2019 Jul 24;21(5):94. doi: 10.1208/s12248-019-0361-7.

PMID:
31342199
2.

Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance.

Hamuro L, Statkevich P, Bello A, Roy A, Bajaj G.

Clin Pharmacol Ther. 2019 Nov;106(5):1018-1027. doi: 10.1002/cpt.1502. Epub 2019 Jul 10.

PMID:
31090921
3.

Surface plasmon resonance as a tool for ligand-binding assay reagent characterization in bioanalysis of biotherapeutics.

Duo J, Bruno J, Kozhich A, David-Brown D, Luo L, Kwok S, Santockyte R, Haulenbeek J, Liu R, Hamuro L, Peterson JE, Piccoli S, DeSilva B, Pillutla R, Zhang YJ.

Bioanalysis. 2018 Apr 1;10(8):559-576. doi: 10.4155/bio-2017-0271. Epub 2018 Apr 27.

PMID:
29701071
4.

Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test.

Hamuro L, Chan P, Tirucherai G, AbuTarif M.

CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):596-603. doi: 10.1002/psp4.12220. Epub 2017 Aug 29.

5.

Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.

Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu DX, Zepeda M, Jawa V.

J Pharm Sci. 2017 Oct;106(10):2946-2954. doi: 10.1016/j.xphs.2017.05.030. Epub 2017 May 31. Review.

PMID:
28576695
6.

Accelerating Regulated Bioanalysis for Biotherapeutics: Case Examples Using a Microfluidic Ligand Binding Assay Platform.

Liu R, Hoffpauir B, Chilewski SD, Gamberdella J, Kavita U, Duo J, Gleason C, Zhang Y, Pillutla R, DeSilva B, Hamuro L.

AAPS J. 2017 Jan;19(1):82-91. doi: 10.1208/s12248-016-0006-z. Epub 2016 Oct 27.

PMID:
27796911
7.

Development and validation of a liquid chromatography tandem mass spectrometry assay for the quantitation of a protein therapeutic in cynomolgus monkey serum.

Zhao Y, Liu G, Angeles A, Hamuro LL, Trouba KJ, Wang B, Pillutla RC, DeSilva BS, Arnold ME, Shen JX.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Apr 15;988:81-7. doi: 10.1016/j.jchromb.2015.02.007. Epub 2015 Feb 16.

PMID:
25756208
8.

A novel and cost effective method of removing excess albumin from plasma/serum samples and its impacts on LC-MS/MS bioanalysis of therapeutic proteins.

Liu G, Zhao Y, Angeles A, Hamuro LL, Arnold ME, Shen JX.

Anal Chem. 2014 Aug 19;86(16):8336-43. doi: 10.1021/ac501837t. Epub 2014 Aug 8.

PMID:
25083595
9.

The effect of the neonatal Fc receptor on human IgG biodistribution in mice.

Chen N, Wang W, Fauty S, Fang Y, Hamuro L, Hussain A, Prueksaritanont T.

MAbs. 2014 Mar-Apr;6(2):502-8. doi: 10.4161/mabs.27765. Epub 2014 Jan 9.

10.

Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.

Chiu CS, Peekhaus N, Weber H, Adamski S, Murray EM, Zhang HZ, Zhao JZ, Ernst R, Lineberger J, Huang L, Hampton R, Arnold BA, Vitelli S, Hamuro L, Wang WR, Wei N, Dillon GM, Miao J, Alves SE, Glantschnig H, Wang F, Wilkinson HA.

J Gerontol A Biol Sci Med Sci. 2013 Oct;68(10):1181-92. doi: 10.1093/gerona/glt030. Epub 2013 Mar 22.

PMID:
23525481
11.

The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in Glycoengineered Pichia Pastoris.

Liu L, Gomathinayagam S, Hamuro L, Prueksaritanont T, Wang W, Stadheim TA, Hamilton SR.

Pharm Res. 2013 Mar;30(3):803-12. doi: 10.1007/s11095-012-0921-3. Epub 2012 Nov 8.

PMID:
23135825
12.

Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs.

Wang W, Chen N, Shen X, Cunningham P, Fauty S, Michel K, Wang B, Hong X, Adreani C, Nunes CN, Johnson CV, Yin KC, Groff M, Zou Y, Liu L, Hamuro L, Prueksaritanont T.

Drug Metab Dispos. 2012 May;40(5):952-62. doi: 10.1124/dmd.111.043604. Epub 2012 Feb 10.

PMID:
22328584
13.

Metabolism of biologics: biotherapeutic proteins.

Hamuro LL, Kishnani NS.

Bioanalysis. 2012 Jan;4(2):189-95. doi: 10.4155/bio.11.304. Review.

PMID:
22250801
14.

Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials.

Liu L, Stadheim A, Hamuro L, Pittman T, Wang W, Zha D, Hochman J, Prueksaritanont T.

Biologicals. 2011 Jul;39(4):205-10. doi: 10.1016/j.biologicals.2011.06.002. Epub 2011 Jul 1.

PMID:
21723741
15.

Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.

Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T.

Drug Metab Dispos. 2011 Sep;39(9):1469-77. doi: 10.1124/dmd.111.039453. Epub 2011 May 24.

PMID:
21610128
16.

Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis.

Roman J, Qiu J, Dornadula G, Hamuro L, Bakhtiar R, Verch T.

J Pharmacol Toxicol Methods. 2011 May-Jun;63(3):227-35. doi: 10.1016/j.vascn.2010.12.002. Epub 2010 Dec 13.

PMID:
21147239
17.

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo.

Ni YG, Di Marco S, Condra JH, Peterson LB, Wang W, Wang F, Pandit S, Hammond HA, Rosa R, Cummings RT, Wood DD, Liu X, Bottomley MJ, Shen X, Cubbon RM, Wang SP, Johns DG, Volpari C, Hamuro L, Chin J, Huang L, Zhao JZ, Vitelli S, Haytko P, Wisniewski D, Mitnaul LJ, Sparrow CP, Hubbard B, CarfĂ­ A, Sitlani A.

J Lipid Res. 2011 Jan;52(1):78-86. doi: 10.1194/jlr.M011445. Epub 2010 Oct 19.

18.

Disruption of protein kinase A localization using a trans-activator of transcription (TAT)-conjugated A-kinase-anchoring peptide reduces cardiac function.

Patel HH, Hamuro LL, Chun BJ, Kawaraguchi Y, Quick A, Rebolledo B, Pennypacker J, Thurston J, Rodriguez-Pinto N, Self C, Olson G, Insel PA, Giles WR, Taylor SS, Roth DM.

J Biol Chem. 2010 Sep 3;285(36):27632-40. doi: 10.1074/jbc.M110.146589. Epub 2010 Jun 26.

19.

Optimization of a polyglutamine aggregation inhibitor peptide (QBP1) using a thioflavin T fluorescence assay.

Hamuro L, Zhang G, Tucker TJ, Self C, Strittmatter WJ, Burke JR.

Assay Drug Dev Technol. 2007 Oct;5(5):629-36.

PMID:
17939755

Supplemental Content

Loading ...
Support Center